Pelvic Inflammatory Disease
Conditions
Interventions
SPID Group.:Cross-sectional study, no intervention.
Healthy Group:Cross-sectional study, no intervention.
Treatment Group:Participants will receive oral administration of Taohong Siwu Decoction, with one dose per day, divided into two portions taken in the morning and evening, for a continuous period of 1
Control Group:Participants will receive oral administration of Kunfukang capsules, with a dosage of 3 capsules per session, taken 3 times daily, for a continuous period of 14 days.
Sponsors
The Second Affiliated Hospital of Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medicine).
Eligibility
Sex/Gender
Female
Age
18 Years to 55 Years
Inclusion criteria
Inclusion criteria: 1. Part One: Investigation of Vaginal Microbiota Structure and Metabolic Characteristics in SPID Patients, Identification of Specific Vaginal Bacteria and Metabolites, and Exploration of the Impact of Vaginal Microecology on Systemic Metabolism and Inflammation. ?Women aged 18-55 years with a history of sexual activity. ?SPID patients meeting the diagnostic criteria for SPID, and healthy controls excluding PID and SPID. ?Willing to participate in the study and provide written informed consent. 2. Part Two: Investigation of Changes in Vaginal Microecology in SPID Patients with Qi Stagnation and Blood Stasis Syndrome After Intervention with Taohong Siwu Decoction. ?Women aged 18-55 years with a history of sexual activity. ? Meeting the diagnostic criteria for SPID with Qi stagnation and blood stasis syndrome. ?Willing to participate in the study and provide written informed consent.
Exclusion criteria
Exclusion criteria: ?Women who are pregnant or breastfeeding. ?Use of antibiotic treatment within 30 days before enrollment and sampling. ?Sexual activity, vaginal or cervical medication, or vaginal douching within 48 hours before specimen collection. ?Severe diseases of major organs such as the heart, brain, liver, kidneys, or blood system, as well as endocrine disorders. ?Undergoing major traumatic surgery.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The improvement of abdominal pain or lumbosacral pain symptoms.;Improvement of pelvic signs;TCM syndrome scores; | — |
Secondary
| Measure | Time frame |
|---|---|
| Vaginal Microecology; | — |
Countries
China
Contacts
Public ContactXiao-Feng Ruan
The Second Affiliated Hospital of Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medicine).
Outcome results
None listed